Shaji Kumar
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 805
- Multiple Myeloma Research and Treatments 751
-
- Protein Degradation and Inhibitors 288
- Amyloidosis: Diagnosis, Treatment, Outcomes 199
- Ubiquitin and proteasome pathways 51
- Co-authors
- S. Vincent Rajkumar (251 shared papers)Angela Dispenzieri (251 shared papers)Morie A. Gertz (251 shared papers)Robert A. Kyle (243 shared papers)Martha Q. Lacy (251 shared papers)Suzanne R. Hayman (251 shared papers)Francis K. Buadi (251 shared papers)David Dingli (251 shared papers)
- Journals
- Blood (282 papers)Journal of Clinical Oncology (101 papers)Leukemia (59 papers)Blood Cancer Journal (59 papers)American Journal of Hematology (58 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Shaji Kumar
959 papers receiving 34.4k citations
Shaji Kumar's Hit Papers
Peers
Comparison fields: 5 of 170
- Hematology 23.4k
- Genetics 5.7k
- Oncology 14.0k
- Molecular Biology 22.8k
- Nephrology 1.6k
Countries citing papers authored by Shaji Kumar
This map shows the geographic impact of Shaji Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaji Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaji Kumar more than expected).
Fields of papers citing papers by Shaji Kumar
This network shows the impact of papers produced by Shaji Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaji Kumar. The network helps show where Shaji Kumar may publish in the future.
Co-authors
The 25 scholars most cited alongside Shaji Kumar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.0k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved survival in multiple myeloma and the impact of novel therapies Hit paper breakdown → | 2007 | 1682 |
| 2 | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Hit paper breakdown → | 2013 | 957 |
| 3 | Multiple myeloma Hit paper breakdown → | 2017 | 755 |
| 4 | Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Hit paper breakdown → | 2009 | 743 |
| 5 | Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements Hit paper breakdown → | 2012 | 730 |
| 6 | New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes Hit paper breakdown → | 2012 | 625 |
| 7 | 2005 | 485 | |
| 8 | Clonal competition with alternating dominance in multiple myeloma Hit paper breakdown → | 2012 | 456 |
| 9 | Multiple Myeloma: Diagnosis and Treatment Hit paper breakdown → | 2016 | 453 |
| 10 | Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance Hit paper breakdown → | 2018 | 351 |
| 11 | 2009 | 324 | |
| 12 | 2012 | 318 | |
| 13 | 2007 | 285 | |
| 14 | 2004 | 267 | |
| 15 | 2004 | 266 | |
| 16 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 256 |
| 17 | 2007 | 252 | |
| 18 | 2010 | 242 | |
| 19 | 2006 | 230 | |
| 20 | 2009 | 226 |
About Shaji Kumar
Shaji Kumar is a scholar working on Hematology, Molecular Biology, Oncology, Genetics and Pathology and Forensic Medicine, having authored 1.0k papers that have together received 35.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (751 papers), Protein Degradation and Inhibitors (288 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (199 papers), Peptidase Inhibition and Analysis (147 papers), Cancer Treatment and Pharmacology (139 papers), Chronic Lymphocytic Leukemia Research (92 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (67 papers) and Ubiquitin and proteasome pathways (51 papers). The work is most often cited by research in Hematology (23.4k citations), Genetics (5.7k citations), Oncology (14.0k citations), Molecular Biology (22.8k citations) and Nephrology (1.6k citations). Shaji Kumar has collaborated with scholars based in United States, France and Spain. Frequent co-authors include S. Vincent Rajkumar, Angela Dispenzieri, Morie A. Gertz, Robert A. Kyle, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, John A. Lust and Philip R. Greipp. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Blood Cancer Journal and American Journal of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.